Daiichi Sankyo will present over 45 abstracts highlighting the progress across its oncology portfolio at the 2024 ESMO Asia Congress,San Antonio Breast Cancer Symposium and The American Society of Hematology Annual Meeting. The research spans a variety of solid and blood cancers, reinforcing the company’s goal of setting new standards of care in cancer treatment.
At ESMO Asia, Daiichi Sankyo will showcase three late-breaking presentations, including a pooled analysis of the TROPION-Lung05 and TROPION-Lung01 trials of datopotamab deruxtecan (Dato-DXd) for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Other key studies include the DESTINY-Breast06 phase 3 trial of ENHERTU® (trastuzumab deruxtecan) in HER2 low breast cancer, and primary analysis from the VALENTINE phase 2 trial of patritumab deruxtecan (HER3-DXd) in early HR positive, HER2 negative breast cancer at the SABCS.
Ken Takeshita, MD, Global Head of R&D at Daiichi Sankyo, emphasized the company’s commitment to advancing therapies for challenging cancers such as lung, breast, gastric, biliary tract cancers, and hematologic conditions like acute myeloid leukemia (AML) and peripheral T-cell lymphoma.
Innovation in Lung, Breast, Gastric, and Biliary Tract Cancer at ESMO Asia A key late-breaking presentation at ESMO Asia will feature pooled data from the TROPION-Lung05 and TROPION-Lung01 trials of datopotamab deruxtecan in EGFR-mutated advanced NSCLC. Other highlights include a mini-oral session presenting results from the TROPION-Breast01 phase 3 trial and DESTINY-Gastric06, which led to ENHERTU’s conditional approval in China for HER2 positive gastric cancer.
Trial-in-progress posters will include the DESTINY-BTC01 phase 3 trial evaluating ENHERTU in combination with rilvegostomig for biliary tract cancer, and the DESTINY-Gastric03 trial exploring ENHERTU’s role in combination with rilvegostomig and chemotherapy for advanced gastric cancer. Additionally, data from the DESTINY-PanTumor02 phase 2 trial will focus on HER2 expressing tumors across multiple cancers.
Continued Progress in Breast Cancer at SABCS At SABCS, Daiichi Sankyo will present a subgroup analysis of the DESTINY-Breast06 trial, highlighting outcomes for patients with HR positive, HER2 low breast cancer, and a primary analysis from the VALENTINE phase 2 trial evaluating patritumab deruxtecan in early breast cancer. Further, exploratory biomarker analyses from the DESTINY-Breast03 and DESTINY-Breast12 trials will provide insight into the impact of genomic alterations and quality of life in patients receiving ENHERTU.
Additionally, posters will showcase the results from the DESTINY-Breast08 trial, evaluating ENHERTU in combination with capecitabine or capivasertib in HER2 low metastatic breast cancer. Trial-in-progress posters will present sub-protocols from phase 1b studies examining ENHERTU in combination with novel agents in patients with metastatic HER2 low or HER2 null breast cancer.
Updates in Hematology at ASH At ASH, Daiichi Sankyo will present data from the QuANTUM-First phase 3 trial of VANFLYTA® (quizartinib) in newly diagnosed FLT3-ITD positive AML. Oral presentations will focus on the frequency of co-mutations and their impact on clinical outcomes. Poster presentations will provide new insights on VANFLYTA’s efficacy and measurable residual disease in AML.
Data will also be presented from the QUIWI phase 2 trial, investigating VANFLYTA in combination with chemotherapy for newly diagnosed FLT3-ITD negative AML, with further sub-analyses based on mutational status. Additionally, data from the VALYM phase 2 trial of valemetostat in relapsed/refractory large B-cell lymphoma and analysis of circulating tumor DNA in peripheral T-cell lymphoma will be featured.
Science & Technology Day Daiichi Sankyo will host its “Science & Technology Day” for investors on December 16, 2024. Executives will provide an overview of the data presented at ESMO Asia, SABCS, and ASH, and offer updates on the company’s R&D strategy.
